Polares Medical Raises $50 million in Series C Funding

The funding was supported by DC Global Ventures, Lumination Capital, existing investors and a new strategic investor, to help advance MR^ace‘s US expansion following strong clinical results.

Polares Medical SA (‘Polares’), a Swiss Health Valley clinical-stage structural heart company developing the MR^ace mitral valve replacement system for mitral valve regurgitation (MR), announced the closing of $50 million in Series C financing. The oversubscribed financing was completed with significant participation from DC Global Ventures, Lumination Partners, existing investors and a new strategic investor.

Polares is focused on the large and growing population of patients suffering from mitral valve regurgitation, a heart valve disease, particularly those with secondary MR, a condition commonly treated with transcatheter edge-to-edge repair (TEER).

Although TEER has transformed the therapeutic landscape, anatomical complexity can limit its applicability in certain patients. The MR^ace mitral valve replacement system is designed to expand transcatheter treatment options to a wide range of mitral anatomies, simplify the procedure and preserve future therapeutic options.

This funding is part of MRace’s clinical acceleration momentum, with more than 70 patients now implanted. This expanded clinical experience has validated the concept of posterior leaflet replacement and generated compelling results. The funds raised will be used to advance clinical studies in the United States, Europe and Australia.

‘We believe that the mitral valve replacement procedure opens a new chapter in transcatheter mitral treatment,’ said Jacques R. Essinger, Ph.D., President and Chief Executive Officer of Polares Medical. ‘With more than 70 patients in clinical experience and encouraging one-year data demonstrating sustained safety and efficacy, we have established a strong foundation for MR^ace. This funding positions us to advance the therapeutic paradigm for complex mitral valve regurgitation.’ “

‘Polares is addressing one of the largest and most strategic markets in structural heart disease with a unique approach,’ said Min Cui, Managing Partner of DC Global Capital. ‘The MR^ace system has the potential to treat a wide range of patients and expand access to mitral valve interventions globally.’

About Polares Medical
Polares Medical SA is a clinical-stage structural heart company developing the MRace mitral valve replacement system, a novel catheter-based therapy designed to treat patients with mitral valve regurgitation. The company is headquartered in Lausanne, Switzerland, and has operations in Palo Alto, California.

➡️ Source: Press Release | 📸 © Polares Medical